Nuvalent, Inc.
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domai…
Biotechnology
US, Cambridge [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -0.93 | -92.17 | -91.32 | |
| Graham Fair Price | 2.55 | 12.81 | 12.49 | |
| PEG | 58.10 | -2.46 | -5.88 | |
| Price/Book | 12.16 | 7.33 | 6.53 | |
| Price/Cash Flow | 9.53 | -137.04 | -151.48 | |
| Prices/Earnings | 6.97 | -27.79 | -29.88 | |
| Price/Sales | 0.00 | 0.00 | 0.00 | |
| Price/FCF | 9.53 | -137.04 | -151.48 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | 0.00 | 0.00 | 0.00 | |
| Operating Margin | 0.00 | 0.00 | 0.00 | |
| ROA | -20.09 | -0.06 | -0.05 | |
| ROE | -0.05 | -0.07 | -20.56 | |
| ROIC | -0.07 | -0.08 | -3.01 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | 0.00 | 0.00 | 0.00 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | -0.20 | -0.13 | 32.88 | |
| EPS QOQ | -0.05 | -0.11 | -122.04 | |
| FCF QOQ | -0.31 | -0.19 | 38.14 | |
| Revenue QOQ | 0.00 | 0.00 | 0.00 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Weak
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 0.00 | 0.00 | 0.00 | |
| Days Sales Outstanding (DSO) | 0.00 | 0.00 | 0.00 | |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | |
| Debt/Capitalization | 0.00 | 0.00 | 0.00 | |
| Quick Ratio | 22.62 | 20.70 | -8.51 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 11.27 | 10.52 | -6.60 | |
| Cash | 11.58 | 10.78 | -6.85 | |
| Capex | 0.00 | 0.00 | 0.00 | |
| Free Cash Flow | -0.49 | -0.56 | -15.79 | |
| Revenue | 0.00 | 0.00 | 0.00 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Bad
Fundamentals
Financial Health
06 - Financial Health ·
Bad